Slovenian doctors achieve world first in autoimmune medicine

LokalecIndependentCenter11 hr. ago

Slovenski raziskovalci iz Pediatrične klinike UKC Ljubljana so objavili zgodovinsko pomembno raziskavo v reviji New England Journal of Medicine, kjer so predstavili nov pristop k zdravljenju avtoimunskih bolezni. Novi pristop temelji na odstranjevanju sprožilcev bolezni namesto zaviranja imunskega sistema, kar lahko vodi do bolj ciljanih in varnejših terapij. Raziskovalci so uporabili encim DNASE1L3 za učinkovitost razgradnjo struktur, kot so nevtrofilne zunajcelične pasti (NET), ki lahko sprožijo kronično vnetje. Prva uporaba novega zdravila pri bolniku s prirojenim sistemskim lupusom eritematozusom je pokazala izjemno hitro izboljšanje kliničnih znakov in laboratorijskih kazalcev, kar je potrjevalo učinkovitost terapije.

Bias read (Center): Čeprav je tematika zdravljenja avtoimunskih bolezni zelo pomembna in zelo znanstvena, ta raziskava ne vključuje političnih stališč ali spora med političnimi skupinami. Vsebina je osredotočena na znanstveni napredek in njegovo primerno uporabo v medicini. Strokovnjaki so predstavili svoje rezultate v

The Slovenia TimesIndependentCenter14 hr. ago

A team of researchers at Slovenia's University Medical Centre Ljubljana achieved a groundbreaking medical milestone by treating a teenager with a rare form of systemic lupus erythematosus through a novel approach. Instead of using traditional immunosuppressive treatments, the team administered an experimental recombinant version of the missing DNASE1L3 enzyme, targeting the root cause of the disease. This treatment led to rapid improvement in the patient's symptoms within six hours. The success of this method, which removes the trigger of the immune response rather than suppressing the immune system, marks a potential paradigm shift in autoimmune disease treatment. The findings were published in the prestigious New England Journal of Medicine, highlighting the significance of this breakthrough. The therapy was developed by US biotech firm Neutrolis and is part of ongoing research aimed at expanding this approach to treat various autoimmune conditions.

Bias read (Center): This article reports on a medical breakthrough with no political implications. It focuses on scientific achievement and healthcare innovation, making it apolitical in nature. As such, it does not exhibit a discernible ideological lean.

DeloIndependent🔒Center16 hr. ago

Raziskovalci na Univerzi v Ljubljani so klinično dokazali nov pristop k zdravljenju avtoimunskih bolezni, ki temelji na odstranitvi sprožilcev bolezni namesto zaviranju imunskega sistema. Rezultati so objavili v reviji New England Journal of Medicine. Novi biološki zdravil, rekombinantni encim DNASE1L3, je uspešno zdravil bolnika s prirojenim sistemskim lupusom eritematozusom, kar je pokazalo, da je možno zdraviti bolezen z odstranjevanjem njenega sprožilca. Dosedanje metode zavirajo delovanje imunskega sistema, kar ima negativne posledice. Nov pristop uporablja nevtrofilske zunajcelične pasti (NET) in jih razgraja z uporabo DNASE1L3, kar prepreči kronično vnetje in avtoimunski odziv. Profesor Tadej Avčin je opisal to kot prvo klinično potrditev novega koncepta zdravljenja avtoimunskih bolezni.

Bias read (Center): Čeprav je tematika zdravstvenih in znanstvenih raziskav, je ta nova metoda zdravljenja avtoimunskih bolezni pomembna za javno zdravje in zdravstveno politiko. Vendar artikel ne izraža nobene politične stranke ali podpore določenemu političnom smerniku. Nekritično poroča o znanstvenem napredku brez v

VečerIndependent🔒Center16 hr. ago

Researchers at the Pediatric Clinic of UKC Ljubljana have successfully treated the first patient in the world using a new therapy for autoimmune diseases. The patient had congenital systemic lupus erythematosus due to a lack of the enzyme DNASE1L3, which made existing treatments ineffective. After receiving a new biological medication—recombinant DNASE1L3—the patient showed rapid improvement within six hours. Laboratory tests confirmed the quick breakdown of neutrophil extracellular traps (NETs), proving the treatment works through the predicted mechanism. This marks the first clinical evidence that autoimmune diseases can be treated by removing their trigger rather than directly suppressing the immune system. The findings were published in the prestigious medical journal New England Journal of Medicine.

Bias read (Center): The article focuses on a scientific breakthrough in medical research and does not involve political figures, policies, or contentious issues. It presents factual information about a successful treatment method without any apparent ideological framing or bias.

RTV Slovenija (MMC)State / PublicCenter17 hr. ago

Researchers at the University of Ljubljana's Pediatric Clinic have successfully treated a patient with a rare form of congenital systemic lupus erythematosus using a new biological therapy. This treatment involves removing the trigger of the disease rather than suppressing the immune system directly. The patient had previously been unresponsive to all known treatments, including modern biological drugs. The breakthrough was achieved through the application of a recombinant enzyme called DNASE1L3, which was used under compassionate use authorization since the drug does not yet have regulatory approval. The results were published in the prestigious medical journal 'New England Journal of Medicine,' marking a significant advancement in the treatment of autoimmune diseases.

Bias read (Center): The article focuses on a scientific medical breakthrough and does not involve any political figures, policies, or contentious issues. It presents factual information about a new treatment method for an autoimmune disease without showing bias toward any particular political stance or ideology.